Skyworks Aeronautics Announces $100 Million Investment Commitment from GEM as Company Seeks to Go Public in Coming Months
5.2.2021 16:00:00 EET | Business Wire | Press release
Skyworks Aeronautics Corp. today announced a $100 million investment commitment from GEM Global Yield LLC SCS ("GEM"), the Luxembourg based private alternative investment group. Under the agreement, GEM will provide Skyworks Aeronautics with a Share Subscription Facility of up to $100 million for a 36-month term following a public listing of the Skyworks Aeronautics common stock. Skyworks Aeronautics will control the timing and maximum amount of drawdowns under this facility and has no minimum drawdown obligation. Concurrent with a public listing of Skyworks Aeronautics shares, Skyworks Aeronautics will issue warrants to GEM to purchase up to 3% of the common stock of the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210205005052/en/
Skyworks Aeronautics VertiJet™ (Photo: Business Wire)
"Skyworks Aeronautics looks forward to working with GEM as we continue to work to bring our cutting-edge aircraft to market," stated Mr. Steve Stevanovich, Skyworks Aeronautics Co-Executive Director. “We think that GEM is an excellent partner that believes in our vision and understands the promise and potential of our technology.”
Skyworks Aeronautics will use the funds to move forward with the commercialization of its cutting-edge gyroplane aircraft, including the eGyro™ electric air taxi geared towards urban air mobility and the 400 mph VertiJet™ VTOL aircraft that competes directly with helicopters, but at a much higher speed, longer range and lower operating cost.
Brig. General (Ret.) John Michel, Skyworks Aeronautics Co-Executive Director added, “With our highly experienced leadership and technical team and strong intellectual property portfolio, this commitment by GEM positions Skyworks Aeronautics to become the first company in the world to commercialize gyrocraft at scale. Be it providing affordable vertical lift alternatives to developing nations, progressive electric aircraft capabilities for air carriers, or game-changing vertical takeoff and landing platforms, Skyworks Aeronautics is now poised to be a transformative force in the rapidly evolving air mobility industry.”
This agreement comes on the heels of Skyworks Aeronautics recent announcement of its electric aircraft collaboration with Mobius.energy to produce the state-of-the-art electric gyroplane, the eGyro™. The Skyworks Aeronautics eGyro™ has been designed to leverage the fundamental safety and exceptional performance advantages of a gyroplane to create an eVTOL system that provides an unparalleled practical, affordable, and scalable approach to intra and inter-city passenger and air cargo transport. With a proprietary autorotating main rotor design delivering exceptional performance and unprecedented safety, the eGyro™ overcomes a key limitation of many of today’s existing eVTOL system concepts. Mobius.energy developed an advanced battery module architecture optimized for electric aircraft.
Amongst other senior and technical staff, Skyworks Aeronautics has also recently added Mr. Barry Jones as its Director of Aviation Operations and Chief Pilot. Mr. Jones, a retired British Army Air Corps Captain, is a highly decorated aviator and instructor in numerous aircraft. He has also served as the Chairman of the British Rotorcraft Association (the organization that governs Gyro flying in the UK), has successfully worked with aviation regulators across Europe on certification matters, and has spent the last decade working in the field of Gyro Research & Development, successfully developing and launching several significant gyroplane enhancing concepts. He is leading Skyworks Aeronautics certification efforts. The full senior leadership team can be viewed on the following link: https://www.skyworks-aero.com/#section-teamone
About Skyworks Aeronautics
Skyworks Aeronautics is the world leader in gyronautics, the study and design of sustained autorotative flight represented by the company's gyroplane technology. Skyworks Aeronautics has more than 40 patents with several more underway, all obtained in an effort to radically change not only the way gyroplanes are perceived, but also the way they are utilized. From mass personnel transportation, agriculture, defense, and border protection to literally changing the economies of developing nations, Skyworks Aeronautics' goal is to change the nature of vertical flight. For more information about the company, its products, and individual members of the Skyworks Aeronautics team, visit www.Skyworks-Aero.com
About GEM
Global Emerging Markets (“GEM”) is a $3.4 billion, alternative investment group with offices in Paris, New York, and Los Angeles. GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 400 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments. For more information: http://www.gemny.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210205005052/en/
Contact information
Steve G. Stevanovich
steve@skyworks-aero.com
+1 312 809 1076
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 10:00:00 EEST | Press release
Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defies convention and empowers individuals to express their identity and bring out confidence. At the heart of this vision is the brand’s signature shadow enhancing makeup approach
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom